Canaccord analyst Sumant Kulkarni raised the firm’s price target on AtaiBeckley (ATAI) to $15 from $14 and keeps a Buy rating on the shares. The firm updated its model following its investor day as they prepare for BPL-003 to enter Phase 3 trials this quarter and wait for VLS-01 Elumina Phase 2 data for TRD in 2H26. The key changes made are is to model a price of net annual price of $30k for BPL–03 at launch versus roughly $20k, which is more in line with Spravato’s net price.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATAI:
- Trump Trade: President to sign order on psychedelic used for PTSD
- AtaiBeckley price target raised to $16 from $11 at Guggenheim
- Buy Rating on Atai Beckley N.V. Driven by Differentiated Psychedelic TRD Program and Favorable Risk‑Reward Profile
- Trump to sign order on psychedelic used for PTSD, CBS News says
- Psychedelic: AtaiBeckley reports publication of BPL-003 study results